Vertex’s most recent drugs to receive approval, Trikafta/Kaftrio, which are triple combination regimens, build on molecules in Symdeko and Kalydeco while layering in a new CFTR corrector ...

Trikafta, made by Vertex Pharmaceuticals, is, as its name suggests, a combination of three drugs. It works for 90 percent of patients with cystic fibrosis, and will be priced at $311,000 per year.

But when she found out about the drug Trikafta, she started thinking, “we can manage this”. Cystic fibrosis is a condition that produces thick and sticky mucus and mainly affects the lungs and ...